Second, this is the first MR study to reveal a possible association between SGLT2 inhibitors and lung cancer, non-melanoma skin cancer, and uterine cancer, which may shed light on the unexplored efficacy of this commonly prescribed medication. The gene discussed is SLC5A2; the disease is lung carcinoma.